SOST and obesity due to melanocortin 4 receptor deficiency: In humans, the administration of anti-sclerostin antibody, romosozumab, to patients with osteoporosis markedly increased bone formation and bone mass but there has been no report that demonstrated an effect of romosozumab in improving obesity.